<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo> (AA) is a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorder</z:e> in children, usually treated with immunosuppressive therapy (IST) including antithymocyte globulin (ATG) and <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>There are no current widely used alternative therapies with comparable efficacy </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a child with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), who developed severe <z:hpo ids='HP_0000212'>gingival hyperplasia</z:hpo> secondary to <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, unresponsive to intensive dental intervention </plain></SENT>
<SENT sid="3" pm="."><plain>When IST was changed to tacrolimus there was a significant improvement in the <z:hpo ids='HP_0000212'>gingival hyperplasia</z:hpo>, but equally important, he achieved complete response of his AA within several months </plain></SENT>
<SENT sid="4" pm="."><plain>The use of tacrolimus in children with AA may be a potential modality of treatment </plain></SENT>
</text></document>